Technological University Dublin

ARROW@TU Dublin
Articles

School of Chemical and Pharmaceutical
Sciences

2016

Piperlongumine (piplartine) and Analogues: Antiproliferative
Microtubule-Destabilising Agents
Mary J. Meegan
Trinity College Dublin, Ireland, mmeegan@tcd.ie

Seema M. Nathwani
Trinity College Dublin, Ireland, nathwans@tcd.ie

Brendan Twamley
Trinity Collge Dublin, Ireland, twamleyb@tcd.ie

See
next
page
additional
authors
Follow
this
andfor
additional
works
at: https://arrow.tudublin.ie/scschcpsart
Part of the Biochemistry Commons, Chemical Actions and Uses Commons, Heterocyclic Compounds
Commons, Medicinal and Pharmaceutical Chemistry Commons, Medicinal Chemistry and Pharmaceutics
Commons, Natural Products Chemistry and Pharmacognosy Commons, Organic Chemicals Commons,
and the Other Chemicals and Drugs Commons

Recommended Citation
Megan, M. et al (2016). Piperlongumine (piplartine) and analogues: antiproliferative microtubuledestabilising agents. European Journal of Medicinal Chemistry,,Vol. 125, no. 5, pp. 453-463. doi: 10.1016/
j.ejmech.2016.09.048

This Article is brought to you for free and open access by
the School of Chemical and Pharmaceutical Sciences at
ARROW@TU Dublin. It has been accepted for inclusion in
Articles by an authorized administrator of ARROW@TU
Dublin. For more information, please contact
arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
Mary J. Meegan, Seema M. Nathwani, Brendan Twamley, Daniela M. Zisterer, and Niamh O'Boyle

This article is available at ARROW@TU Dublin: https://arrow.tudublin.ie/scschcpsart/65

Final Draft of:
Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising
agents
Meegan, M.J., Nathwani, S., Twamley, B., Zisterer, D.M., O'Boyle, N.M.*
European Journal of Medicinal Chemistry
Volume 125, 5 January 2017, Pages 453-463
DOI: http://dx.doi.org/10.1016/j.ejmech.2016.09.048

Piperlongumine (Piplartine) and Analogues: Antiproliferative Microtubule-Destabilising
Agents
Mary J. Meegan,1 Seema Nathwani,2 Brendan Twamley,3 Daniela M. Zisterer,2 Niamh M.
O’Boyle1,2*
1

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.

2

School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, 152-160 Pearse

Street, Trinity College Dublin, Dublin 2, Ireland.
3

School of Chemistry, Trinity College Dublin, Dublin 2, Ireland.

*Corresponding author; email oboyleni@tcd.ie

1

ABSTRACT
Piperlongumine (piplartine, 1) is a small molecule alkaloid that is receiving intense interest due to
its antiproliferative and anticancer activities. We investigated the effects of 1 on tubulin and
microtubules. Using both an isolated tubulin assay, and a combination of sedimentation and
Western blotting, we demonstrated that 1 is a tubulin-destabilising agent. This result was
confirmed by immunofluorescence and confocal microscopy, which showed that microtubules in
MCF-7 breast cancer cells were depolymerised when treated with 1. We synthesised a number of
analogues of 1 to explore structure-activity relationships. Compound 13 had the best cytotoxic
profile of this series, showing potent effects in human breast carcinoma MCF-7 cells whilst being
relatively non-toxic to non-tumorigenic MCF-10a cells. These compounds will be further
developed as potential clinical candidates for the treatment of breast cancer.
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1. INTRODUCTION
Cancer is the uncontrolled growth and spread of cells. Annually, 8.2 million deaths are attributable
to cancer, an estimated 13% of all deaths worldwide, and breast cancer accounts for over half a
million of these. The total number of new cases is expected to rise by 70% over the next two
decades [1]. The continuous development of new, cost-effective drug therapies is crucial to
increase the range of options available to patients, and to improve their long-term prognosis.
Piperlongumine (also known as piplartine, 1, Figure 1) is an alkaloid isolated from a number of
Piper plant species, including the long pepper plant Piper longum L. It has a large number of
reported uses in traditional medicine, and has demonstrated cytotoxic and antitumour activity [2].
In particular, it was found to be selectively toxic to cancer cells by increasing the level of reactive
oxygen species (ROS) and inducing apoptotic cell death, although the exact mechanisms of action
remain unclear [3]. Compound 1 has been recently reported to be a direct STAT3 inhibitor [4], a
proteasome inhibitor [5], to promote autophagy [6], and to modulate NF-κB and NF-κB-regulated
gene products [7].
Compound 1 is a chalcone-type molecule, consisting of two ring systems linked by a α-βunsaturated carbonyl chain. One of the rings is aromatic and substituted with three methoxy
groups, while the second is a piperidinone-type ring containing a conjugated alkene. Compound 1
is structurally similar to a number of known tubulin-targeting antiproliferative compounds. These
include combretastatin A-4 (2) and chalcone 3 (Figure 1), both containing a trimethoxyphenyl
3

moiety [8]. An analogue of 2 with a substituted pyridone ring (4, Figure 1) also displays potent
antitubulin activity [9]. A hybrid of compounds 1 and 2 was recently reported as a tubulin
depolymerising agent [10]. Considering these results, we undertook to investigate if 1 has inherent
tubulin- and microtubule-targeting activity in breast cancer cells. We also synthesised a number of
analogues of 1 to investigate structure-activity relationships of the trimethoxyphenyl group of 1
on the antiproliferative potency in breast cancer cells.
2. RESULTS and DISCUSSION
2.1. Chemistry
Previous research has examined the structure-activity relationships of the piperidinone ring of 1
[11]. Hence, we sought to examine the effects of modifying the trimethoxyphenyl ring. The
trimethoxyphenyl ring has repeatedly been shown to be crucial for the tubulin-depolymerising
ability of a number of compounds, including colchicine, podophyllotoxin and 2 [12-14]. These
trimethoxyphenyl-containing compounds bind at the colchicine-binding site on tubulin, mainly
located in the β-subunit. A number of analogues of 1 with different substituents were chosen for
synthesis, in order to better understand the contribution of the trimethoxyphenyl ring to the
antiproliferative activity of 1. Synthesis was achieved in two steps via the key intermediate 5,6dihydropyridin-2(1H)-one.
5,6-Dihydropyridin-2(1H)-one (6) was synthesised in two steps from but-3-en-1-amine via N-(but3-en-1-yl)acrylamide (5) (Scheme 1, steps i and ii). Compound 1 and seven analogues (7-13) were
obtained in moderate yields via a one-pot reaction between 6 and appropriately substituted
cinnamic acids, pre-activated with pivaloyl chloride (Scheme 1, steps iii and iv, 61-72% yield)[15].
1

H NMR coupling constants (15-16 Hz) indicated a trans configuration around the linear α,β-
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unsaturated double bond. An X-ray crystallographic study of 12 confirmed the structure, featuring
a non-planar piperidinone ring and a 3,4-dimethoxyaryl ring (Figure 2). The length of the double
bond in the lactam ring agrees with the published structure for 1 (1.329 Å compared to 1.322 Å)
[16]. The C-N bonds in the lactam ring are unequal with lengths of 1.482 Å (C1-N6) compared to
1.390 Å (C5-N6). The 3-methoxy and 4-methoxy groups are approximately co-planar with the
aromatic ring (torsion angles 5.6 (2)° and 176.8 (13)° respectively). The linear α,β-unsaturated
double bond adopts the predicted trans configuration, with a bond length of 1.335 Å (1.329 Å
reported)[16].
2.2. Biochemistry
2.2.1. Cell Viability
Compound 1 was first tested for its effects on viability in two human cell lines, MCF-7 breast
cancer cells and Jurkat T-lymphocytes. The concentration of 1 required to inhibit the growth of
MCF-7 and Jurkat cells by 50% (IC50) was determined to be 1.2 ± 0.6 μM and 1.4 ± 0.3 μM
respectively at 48 hr (Figure 3A). These are similar to previously reported values for 1 (8 μM in
MCF-7 cells and 5 μM in Jurkat cells) [17, 18]. Cell viability results for 1 in a large number of
cancer cell lines have been determined and, in general, IC50 values range between 1-10 μM [2].
IC50 values for compounds 7-13 were found to be between 3.4 and 9.6 μM in MCF-7 cancer cells,
with 7, 12 and 13 showing the best activity (IC50 values of 3.5, 3.7 and 3.4 μM respectively)(Table
1). Mono-methoxylated compounds 8, 9 and 10 showed decreased potency indicating that one
methoxy group is detrimental to antiproliferative activity, regardless of its position on the ring (2, 3-, or 4-methoxy). Comparison of di-methoxylated compounds 11 and 12 reveals that a 2,3methoxy substitution pattern is preferable to 1,3-methoxy (IC50 values of 8.5 and 3.7 μM
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respectively). These analogues were also assessed for toxicity using non-tumorigenic MCF-10a
mammary epithelial cell line (Figure 3B and Figure S1, Supporting Information). None of the
compounds had any effect on viability of MCF-10a cells at a concentration of 1 μM (24 and 48 hr)
and minimal effects were noted at 5 μM (>90% viability for all compounds at 24 hr, and >80%
viability at 48 hr). The best selectivity at 5 μM was observed for compounds 7, 12 and 13
(differences of 53, 46 and 48% in cell viability of MCF-10a compared to MCF-7, respectively).
Significant effects on MCF-10a cell viability were observed at 10 μM, equal to the effect on MCF7 viability in most cases. Treatment with 1 (10 μM) caused a 90% reduction in cell viability. This
indicates poor selectivity for cancer cells at this concentration, with the exception of compound
13. Compound 7 showed the highest toxicity at 48 hr (Figure 3B). On the basis of combined results
in MCF-7 and MCF-10a cells, compounds 12 and 13 were identified as the best candidates for
future development.
2.2.2. Effect of Pre-treatment with Antioxidants on Cellular Viability
Compound 1 has been reported as an agent that increases the level of ROS in cells [3]. To
investigate the potential effects of our analogues 7-13 on ROS levels in MCF-7 breast cancer cells,
we employed a viability assay in which cells are pre-incubated with an antioxidant prior to
treatment with the compound of interest (Figure 4). This assay indicates potential involvement of
ROS in a compound’s mechanism of action. Two antioxidants were used: N-acetyl cysteine (NAC)
and the vitamin E derivative Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).
The antioxidant concentrations used were shown to have no effect on cell viability. Trolox (100
μM and 300 μM) has been shown to be an effective antioxidant in MDA-MB-231 breast cancer
cells and MIA PaCa-2 pancreatic cancer cells [19]. We also evaluated a number of known tubulindestabilising agents [colchicine, 2 and four chalcones (14-17, Figure 5)]. These compounds were
6

chosen on the basis of structural similarity to 1 (all with the exception of colchicine contain a linear
double bond linking two ring systems, one of which is substituted with 2 or more methoxy groups),
antiproliferative potency, and tubulin-targeting activity. These chalcones were synthesised and
characterised by published procedures (compound 14 [8], 15 [20], 16 [8], 17 [21]).
Firstly, the effects of 1 and representative compounds 7, 12 and 13, alone and in combination with
NAC and Trolox were assessed. Pre-treatment for 1 hr with NAC has a dramatic protective effect
on MCF-7 cells at all concentrations of all compounds tested (Figure 4). Viability increases were
generally greater than 50%, with the highest increase of 73% (compound 7, 10 μM). No significant
increases in cell viability were noted when cells were pre-treated with Trolox. Similar results show
that pre-treatment with NAC but not Trolox has an effect on activity of 1 [19]. Compound 1 is a
relatively reactive compound, due to the reactive α,β-unsaturated carbonyl system contained in the
piperidinone ring. It has been shown to directly bind to NAC (200 equiv. in Hepes buffer; 24 hr
reaction)[19] and to the small-molecule thiol methyl thioglycolate (3 equiv. in DMSO; 72 hr
reaction)[11]. It is possible that this reaction occurs in the aqueous media of cell viability assay,
thus inactivating the α,β-unsaturated carbonyl group of 1. This reaction is not possible with Trolox.
The same considerations apply to analogues 7, 12 and 13. This is a potential reason for the different
effects observed with the two different antioxidants. The differing concentrations of NAC and
Trolox may also play a part.
Secondly, effects of antioxidant pre-treatment on cell viability were assessed for known tubulintargeting compounds. Cells pre-treated with NAC showed increased viability for all compounds
compared to cells that were not pre-treated (Figure 6). Highest increases were noted for 2 (100
nM; 22%) and chalcone 14 (35%). Increases in viability were greater than 10% for all
concentrations of the six compounds evaluated. Similar results were obtained for a lower
7

concentration of 16 and 17 (1 μM; data not shown). Cells pre-treated with Trolox showed slightly
increased viability but effects were generally minimal (Figure 6). The highest increase in viability
was 11.4% for 2 (10 μM). Viability was increased by less than 10% for chalcones 14-17.
The results from the viability assay of colchicine, 2 and chalcones 14-17 indicate potential ROS
involvement in cancer cell death. This has not been reported for 2 or chalcones 14-17 previously
and is worthy of further investigation. A number of known tubulin-targeting agents also have
effects on reactive oxygen species in cells. Paclitaxel, a microtubule-stabilising agent, has been
reported to generate ROS by activating plasma-membrane associated NADPH oxidase
(NOX)[22]. Vinca alkaloids, clinically used microtubule-destabilising agents, induce apoptosis in
lung adenocarcinoma cells via ROS accumulation [23]. Isothiocyanates known to induce oxidative
stress have subsequently been shown to induce degradation of cellular tubulin by proteasomes
[24].

An analogue of colchicine, Green-1, was reported as increasing ROS production in

pancreatic cancer cells and leukaemia cells but its structural modification led to loss of its ability
to depolymerise tubulin [25]. It appears that there is a link between ROS levels and the behaviour
of microtubules in cells. Given the advanced status of 2 in phase II clinical trials, it is important to
fully elucidate its cellular effects [21].
2.2.3. Effects of Piperlongumine on the Cell Cycle and Apoptosis
Further biochemical work was carried out to explore the type of cell death induced by 1. The
effects of 1 on the cell cycle of MCF-7 cells were evaluated. Flow cytometric analysis of propidium
iodide stained cells demonstrated simultaneous decreases in the G0G1 cell population [16 % and
15 % (24 hr), and 21 % and 19 % (48 hr) for 10 and 20 μM respectively] and increases in the G2/M
cell population [13 %, 16 % and 12 % (24 hr), and 6 %, 15 % and 10 % (48 hr) for 5, 10 and 20

8

μM respectively] (Figure 7A). There was a small, statistically significant increase in the percentage
of apoptotic cells (sub-G0G1) after 48 hr (10 and 20 μM of 1; 4.3 and 4.9% respectively).
Due to the increase in apoptotic cells, further effects of 1 on anti-apoptotic proteins of the Bcl-2
protein family were investigated, namely Bcl-2 and Mcl-1. These proteins contribute to an
increased apoptotic threshold in cancer cells and allow cells to survive in stressful environments.
Treatment with 1 (10 μM) caused downregulation of the expression of Bcl-2 and Mcl-1 as
demonstrated by western blotting (Figure 7B). Expression of Bcl-2 was downregulated at 48 hr,
whereas expression of Mcl-1 was evidenced after 72 hr. These results are in agreement with
previous reports of 1-induced apoptosis in MCF-7 cells after 36 hr, evidenced by annexin V/PI
double-staining and PARP cleavage [26]. Compound 1 also reportedly induces both apoptosis and
necrosis in leukaemia cell lines [17], and apoptosis in Burkitt lymphoma cell lines [27], prostate
cancer cells [28], and triple-negative breast cancer cells [18].
Tubulin-destabilising agents often cause increased cell accumulation in the G2/M phase, due to
defective mitotic checkpoints, as found for 1 in MCF-7 cells above. A number of previous studies
have noted G2/M arrest upon treatment with 1, including in Chinese hamster lung fibroblasts
(V79),[29] OVCAR3 human ovarian cancer cells [30] and PC-3 prostate carcinoma cells [28].
This suggests that 1 may potentially target tubulin. The structural similarity of 1 to a number of
known tubulin-destabilizing agents (Figure 1) strengthens this hypothesis. To investigate further,
specific tubulin assays were performed.
2.2.4. Effects of Piperlongumine on Tubulin Polymerisation and Interaction with ColchicineBinding Site

9

The tubulin-targeting properties of 1 were firstly examined in vitro using isolated bovine tubulin
(Figure 8A). The effect of test compounds 1 and 7 on tubulin polymerization was determined by
reading absorbance at 340 nm over 60 min, as the extent of light-scattering by microtubules is
proportional to their degree of polymerisation [31]. Paclitaxel, a known microtubule-stabilising
agent, was used as a control and increased the final polymer mass (Figure 8A). Depolymerisation
of tubulin and reduction in the final polymer mass was noted for the higher concentration of 1 (25
μM, Figure 8A). A similar but less pronounced effect was seen for compound 7 (25 μM).
Compound 1 was selected for further investigation in MCF-7 breast cancer cells and Jurkat Tlymphocytes.
A cellular assay based on sedimentation followed by western blotting were used to examine the
effects of 1 on tubulin polymerisation in both MCF-7 and Jurkat cells (Figure 8B). Polymerized
and depolymerized microtubules have different solubilities and localize preferentially in the pellet
or supernatant of lysed, centrifuged cells, respectively [32]. Paclitaxel (a microtubule-stabilising
agent) and nocodazole (a microtubule-destabilising agent) were used as controls. As expected,
tubulin from nocodazole-treated cells was depolymerized and detected almost wholly in the
supernatant, whereas tubulin from paclitaxel-treated cells was polymerized and detected solely in
the pellet (Figure 8B). Tubulin from cells treated with 1 (10 μM) was found exclusively in the
supernatant, indicating complete depolymerization of tubulin (Figure 8B). Similar results were
obtained for 5 μM and 20 μM concentrations of 1. Equal amounts of tubulin were detected in the
supernatants and pellets of cells treated with 1 μM of 1, indicating that this concentration does not
have an effect on tubulin polymerization in MCF-7 and Jurkat cells (data not shown).
Finally, a second cellular assay to examine the effects of 1 on the microtubule network of MCF-7
cells was carried out using immunofluorescence and confocal microscopy. Cells were again treated
10

with either paclitaxel, known microtubule-destabilising agent 2, or 1. Vehicle-treated cells
displayed organised microtubule structures (Figure 9). Cells treated with the microtubulestabilising agent paclitaxel exhibited characteristic bundling, whereas cells treated with 2 showed
disruption of the microtubule network. Cells treated with a higher concentration of 1 (20 μM)
showed a disorganised microtubule structure, consistent with depolymerised tubulin. A lower
concentration of 10 μM caused less depolymerisation, with some polymerised microtubules still
present (Figure 9). These results provide further evidence that 1 is a direct microtubuledestabilising agent.
Compound 1 is structurally similar to a number of tubulin-depolymerising agents, including 2,
which bind to the colchicine-binding site on tubulin. Potential binding of 1 at the colchicinebinding site was therefore investigated using a whole-cell based assay. N,N’-Ethylenebis(iodoacetamide) (EBI) is an alkylating agent that cross-links cysteine residues at positions 239
and 354 in the colchicine-binding site of tubulin, forming a β-tubulin-EBI adduct. This adduct is
detectable by Western blotting as an immunoreactive band that migrates faster than β-tubulin.
Microtubule-destabilising agents that bind at the colchicine-site, such as 2, prevent the formation
of the β-tubulin-EBI adduct [33]. MCF-7 cells were treated with vehicle control, 2 (10 μM) or 1
(40 μM) for 2 h, followed by EBI for an additional 1.5 h (Figure 10). Control samples show the
presence of the β-tubulin-EBI adduct at a lower position, indicating that EBI has cross-linked
Cys239 and Cys354 on β-tubulin. Adduct formation was inhibited in cells treated with 2,
confirming that 2 binds to the colchicine-binding site, whereas 1 did not inhibit the formation of
the β-tubulin-EBI adduct. Similar results were found in HT-29 cells (Figure 10). This indicates
that 1 does not bind at the colchicine-site of tubulin. It is also possible, due to the presence of
reactive α,β-unsaturated groups, that compound 1 itself could cross-link cysteine residues on
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tubulin. It has a similar molecular weight to EBI (317 and 396 respectively) and so an adduct
between β-tubulin and 1 would migrate a similar distance to that of a β-tubulin−EBI adduct.
Further work is required to determine where, and how, 1 interacts with tubulin.
3. Conclusion
Piperlongumine (piplartine) 1, a small molecule which has been receiving huge interest of late, has
been shown for the first time to target tubulin, by destabilising microtubules in MCF-7 breast
cancer cells and Jurkat T-lymphocytes. This effect was confirmed by in vitro tubulin
polymerisation, sedimentation and western blotting, and combined immunofluorescence and
confocal microscopy. A series of analogues of 1 were synthesised and evaluated for
antiproliferative activity, from which compound 13 was identified as having the best toxicity
profile when comparing its effects on viability in MCF-7 breast cancer cells and non-tumorigenic
MCF-10a breast epithelial cells. It was also shown that combretastatin A-4 (2) and colchicine,
established tubulin-destabilising agents, may target the stress response to ROS in MCF-7 breast
cancer cells. The results of this work are an important contribution to further understanding the
intricate biochemical and biological mechanisms of action of 1.
4. EXPERIMENTAL METHODS
All reagents were commercially available and were used without further purification unless
otherwise indicated. Anhydrous dichloromethane was obtained by distillation from calcium
hydride immediately prior to use. 1H and
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C NMR spectra were obtained on a Bruker Avance

DPX 400 instrument at 20oC, 400.13 MHz for 1H spectra, 100.61 MHz for 13C spectra, in either
CDCl3, CD3COCD3 or CD3OD (internal standard: TMS). HRMS for all final compounds were
obtained on a Micromass Time of Flight mass spectrometer (TOF) equipped with electrospray
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ionization (ES) interface operated in positive ion mode at the High Resolution Mass Spectrometry
Laboratory by Mr. Brian Talbot in the School of Pharmacy, Trinity College Dublin. TLC was
performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent indicator visualizing
with UV light at 254nm. Flash chromatography was carried out using standard silica gel 60 (230400 mesh) obtained from Merck. All products isolated were homogenous on TLC. The purity of
the tested compounds was determined by HPLC and, unless otherwise stated, the purity level was
>95%. Analytical high-performance liquid chromatography (HPLC) was performed using a
Waters 2487 Dual Wavelength Absorbance detector, a Waters 1525 binary HPLC pump and a
Waters 717plus Autosampler. The column used was a Varian Pursuit XRs C18 reverse phase 150
x 4.6mm chromatography column. Samples were detected using a wavelength of 254 nm. All
samples were analyzed using acetonitrile (70%): water (30%) over 10 min and a flow rate of 1
mL/min.
4.1. N-(But-3-en-1-yl)acrylamide (5)(Ref. [15]). Triethylamine (2.95 mL, 21.12 mmol) was
added to a stirred solution of but-3-en-1-amine (1 g, 14.08 mmol) in DCM (20 mL) at 0 °C.
Acryloylchloride (1.2 equiv., 1.6 mL, 16.90 mmol) was added and the mixture was allowed to stir
at room temperature for 3 hr. The reaction mixture was diluted with water, and then extracted into
DCM (2 × 10 mL). The solvent was removed in vacuo and the crude product was purified by flash
column chromatography on silica gel using CH2Cl2: methanol (9:1) to give a yellow liquid (56%
yield). 1H NMR (CDCl3) δ 2.26 (2 H, q, J=6.7 Hz), 3.36 (2 H, q, J=6.7 Hz), 4.99 - 5.12 (2 H, m)
5.59 (1 H, dd, J=9.7, 1.0 Hz), 5.74 (1 H, ddt, J=17.1, 10.4, 6.7, 6.7 Hz), 6.11 (1 H, dd, J=17.1,
10.4 Hz), 6.22 (1 H, dd, J=16.8, 1.5 Hz), 6.32 (1 H, s[br]); 13C NMR (CDCl3) δ 33.5, 38.5, 117.0,
126.0, 130.9, 135.1, 165.7; HRMS (ESI): m/z calcd for C7H11NO + H+ (M + H)+: 126.0913; found:
126.0911.
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4.2. 5,6-Dihydropyridin-2(1H)-one (6)(Ref. [15]). Grubbs-II catalyst (42 mg, 5 mol %) was
added to a solution of 5 (0.125 g, 1 mmol) in anhydrous DCM (160 mL) and refluxed for 6 hr
under inert conditions. The mixture was stirred for an additional 1 hr at room temperature in open
air to deactivate the catalyst. The reaction mixture was filtered through celite, concentrated, and
the residue was purified by column chromatography on silica gel using hexane/EtOAc (1:1) to
give a brown liquid (52% yield). 1H NMR (CDCl3) δ 2.35-2.36 (2H, m), 3.43 (2H, td, J = 7.0, 2.5
Hz), 5.91 (1H, dd, J=10.0, 2.1 Hz), 6.65 (1H, dt, J=10.0, 4.4 Hz); 13C NMR (CDCl3) δ 23.8, 39.7,
124.8, 141.4, 166.3; HRMS (ESI): m/z calcd for C5H7NO + Na (M + Na)+: 120.0425; found:
120.0419.
4.3. Synthesis of compounds 7-13.
General Method I: To a solution of cinnamic acid analogue (0.875 mmol), in freshly distilled
THF (5 mL) was added triethylamine (0.10 mL). Pivaloyl chloride (0.69 mmol) was added at 20°C and the reaction mixture was stirred for 45 min. To a solution of 6 (1.05 mmol) in freshly
distilled THF (5 mL) was added n-BuLi (1.2 equiv) at -78°C under inert atmosphere conditions
and the reaction was stirred for 45 min. Then, anhydride prepared from the above step was added
and the reaction mixture was stirred for 1h. The reaction mixture was quenched with saturated
NH4Cl (2 mL), extracted with ethyl acetate (2  10 mL), the organic layer was separated and
washed with sat. NaCl (2 x 6 mL) and dried over anhydrous Na2SO4. The residue was evaporated
in vacuo to give a crude product which was finally purified by column chromatography on silica
gel using hexane/EtOAc (6:4) as eluent to give yellow solid piperlongumine analogue.
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4.3.1. 1-Cinnamoyl-5,6-dihydropyridin-2(1H)-one (7) was obtained from 6 and cinnamic acid
as a colourless oil (72% yield). 1H NMR (CDCl3) δ 2.45 - 2.52 (2 H, m) 4.05 (2 H, t, J=6.43 Hz)
6.05 (1 H, dt, J=9.85, 1.71 Hz) 6.92 - 6.98 (1 H, m) 7.36 - 7.39 (3 H, m) 7.57 - 7.61 (2 H, m) 7.76
(1 H, d, J=15.34 Hz) ; 13C NMR (CDCl3) δ 24.79 (1 C, s) 41.60 (1 C, s) 121.84 (1 C, s) 125.83 (1
C, s) 128.32 (1 C, s) 128.74 (1 C, s) 130.02 (1 C, s) 135.07 (1 C, s) 143.59 (1 C, s) 145.44 (1 C, s)
165.78 (1 C, s) 168.96 (1 C, s); HRMS (ESI): m/z calcd for C14H13NO2 + Na (M + Na): 250.0838;
found: 250.0845.

4.3.2. (E)-1-(3-(2-Methoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (8) was obtained
from 6 and 2-methoxycinnamic acid as a yellow oil (68% yield). 1H NMR (CDCl3) δ ppm 2.44 2.51 (2 H, m) 3.89 (3 H, s) 4.04 (2 H, t, J=6.53 Hz) 6.05 (1 H, d, J=10.04 Hz) 6.89 - 6.99 (3 H, m)
7.34 (1 H, t, J=7.78 Hz) 7.53 - 7.64 (2 H, m) 8.10 (1 H, d, J=15.56 Hz) ; 13C NMR (CDCl3) δ ppm
24.78 (1 C, s) 41.61 (1 C, s) 55.48 (1 C, s) 111.02 (1 C, s) 120.58 (1 C, s) 122.09 (1 C, s) 124.08
(1 C, s) 125.88 (1 C, s) 128.85 (1 C, s) 131.25 (1 C, s) 138.96 (1 C, s) 145.28 (1 C, s) 158.45 (1 C,
s) 165.77 (1 C, s) 169.39 (1 C, s); HRMS (ESI): m/z calcd for C15H15NO3 + Na (M + Na):
280.0944; found: 280.0951.
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4.3.3. (E)-1-(3-(3-Methoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (9) was obtained
from 6 and 3-methoxycinnamic acid as a colourless oil (65% yield). 1H NMR (CDCl3) δ ppm 2.61
- 2.71 (2 H, m) 4.00 (3 H, d, J=2.51 Hz) 4.17 - 4.26 (2 H, m) 6.22 (1 H, d, J=9.54 Hz) 7.05 - 7.16
(2 H, m) 7.36 (1 H, d, J=6.53 Hz) 7.41 - 7.50 (1 H, m) 7.66 (1 H, dd, J=16.06, 2.51 Hz) 7.84 - 7.94
(1 H, m);
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C NMR (CDCl3) δ ppm 24.74 (1 C, s) 41.57 (1 C, s) 55.25 (1 C, s) 112.99 (1 C, s)

116.01 (1 C, s) 121.03 (1 C, s) 122.05 (1 C, s) 125.72 (1 C, s) 129.70 (1 C, s) 136.39 (1 C, s)
143.48 (1 C, s) 145.53 (1 C, s) 159.75 (1 C, s) 165.75 (1 C, s) 168.90 (1 C, s); HRMS (ESI): m/z
calcd for C15H15NO3 + Na (M + Na): 280.0944; found: 280.0960.

4.3.4. (E)-1-(3-(4-Methoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (10) was obtained
from 6 and 4-methoxycinnamic acid as a white powder (67% yield). 1H NMR (CDCl3) δ 2.47 (2
H, d, J=5.52 Hz) 3.84 (3 H, s) 4.04 (2 H, t, J=6.53 Hz) 6.05 (1 H, d, J=10.04 Hz) 6.87 - 6.97 (3 H,
m) 7.42 (1 H, d, J=15.56 Hz) 7.55 (2 H, d, J=8.53 Hz) 7.74 (1 H, d, J=15.56 Hz); 13C NMR (CDCl3)
δ 24.80 (1 C, s) 41.61 (1 C, s) 55.34 (1 C, s) 114.19 (1 C, s) 119.37 (1 C, s) 125.92 (1 C, s) 127.83
(1 C, s) 130.03 (1 C, s) 143.63 (1 C, s) 144.41 (1 C, s) 145.31 (1 C, s); HRMS (ESI): m/z calcd for
C15H15NO3 + Na (M + Na): 280.0944; found: 280.0951.
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4.3.5.

(E)-1-(3-(2,4-Dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one

(11)

was

obtained from 6 and 2,4-dimethoxycinnamic acid as a yellow oil (63% yield). 1H NMR (CDCl3) δ
2.42 - 2.49 (2 H, m) 3.87 (4 H, s) 3.84 (3 H, s) 4.03 (2 H, t, J=6.43 Hz) 6.01 - 6.06 (1 H, m) 6.44
(1 H, d, J=2.07 Hz) 6.49 (1 H, dd, J=8.50, 2.28 Hz) 6.88 - 6.95 (1 H, m) 7.46 - 7.57 (2 H, m) 8.05
(1 H, d, J=15.76 Hz); 13C NMR (CDCl3) δ 24.82 (1 C, s) 41.60 (1 C, s) 55.41 (1 C, s) 55.49 (1 C,
s) 98.31 (1 C, s) 105.16 (1 C, s) 117.33 (1 C, s) 119.55 (1 C, s) 126.02 (1 C, s) 130.33 (1 C, s)
139.23 (1 C, s) 145.02 (1 C, s) 159.91 (1 C, s) 162.62 (1 C, s) 165.78 (1 C, s) 169.60 (1 C, s);
HRMS (ESI): m/z calcd for C16H17NO4 + Na (M + Na): 310.1050; found: 310.1044.

4.3.6.

(E)-1-(3-(3,4-Dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one

(12)

was

obtained from 6 and 3,4-dimethoxycinnamic acid as a pale yellow powder (64% yield). 1H NMR
(CDCl3) δ 2.48 (2 H, tdd, J=6.48, 6.48, 4.25, 1.87 Hz) 3.92 (6 H, d, J=2.07 Hz) 4.05 (2 H, t, J=6.63
Hz) 6.05 (1 H, dt, J=9.74, 1.97 Hz) 6.86 (1 H, d, J=8.29 Hz) 6.94 (1 H, dt, J=9.85, 4.20 Hz) 7.11
(1 H, d, J=2.07 Hz) 7.17 (1 H, dd, J=8.50, 1.87 Hz) 7.42 (1 H, d, J=15.34 Hz) 7.73 (1 H, d, J=15.34
Hz); 13C NMR (CDCl3) δ 24.80 (1 C, s) 41.61 (1 C, s) 55.88 (1 C, s) 55.93 (1 C, s) 109.89 (1 C,
s) 110.93 (1 C, s) 119.54 (1 C, s) 122.93 (1 C, s) 125.90 (1 C, s) 128.10 (1 C, s) 143.93 (1 C, s)
145.34 (1 C, s) 149.10 (1 C, s) 150.99 (1 C, s) 165.85 (1 C, s) 169.05 (1 C, s); HRMS (ESI): m/z
calcd for C16H17NO4 + Na (M + Na): 310.1050; found: 310.1043.

17

4.3.7. (E)-1-(3-(2,4,5-Trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (13) was
obtained from 6 and 2,4,5-trimethoxycinnamic acid as a bright yellow powder (61% yield). 1H
NMR (CDCl3) δ 2.47 (2 H, tdd, J=6.43, 6.43, 4.35, 1.87 Hz) 3.88 (6 H, d, J=1.66 Hz) 3.93 (3 H,
s) 4.04 (2 H, t, J=6.43 Hz) 6.04 (1 H, dt, J=9.74, 1.76 Hz) 6.50 (1 H, s) 6.92 (1 H, dt, J=9.74, 4.25
Hz) 7.10 (1 H, s) 7.46 (1 H, d, J=15.76 Hz) 8.11 (1 H, d, J=15.76 Hz); 13C NMR (CDCl3) δ 24.83
(1 C, s) 41.63 (1 C, s) 56.01 (1 C, s) 56.45 (1 C, s) 56.50 (1 C, s) 96.96 (1 C, s) 110.91 (1 C, s)
115.85 (1 C, s) 119.30 (1 C, s) 126.01 (1 C, s) 138.89 (1 C, s) 143.24 (1 C, s) 145.10 (1 C, s)
152.04 (1 C, s) 154.08 (1 C, s) 165.84 (1 C, s) 169.45 (1 C, s); HRMS (ESI): m/z calcd for
C17H19NO5 + Na (M + Na): 340.1155; found: 340.1160.

4.4. Crystal Structure Report for Compound 12. A specimen of C16H17NO4, approximate
dimensions 0.050 mm x 0.140 mm x 0.300 mm, was used for the X-ray crystallographic analysis.
The X-ray intensity data were measured at 100(2)K using an Oxford Cryosystems low temperature
device using a MiTeGen micromount. Bruker APEX software was used to correct for Lorentz and
polarization effects. A total of 360 frames were collected. The total exposure time was 7.00 hours.
The integration of the data using a monoclinic unit cell yielded a total of 20430 reflections to a
maximum θ angle of 26.80° (0.79 Å resolution), of which 2947 were independent (average
redundancy 6.932, completeness = 99.5%, Rint = 6.24%, Rsig = 3.74%) and 2189 (74.28%) were
greater than 2σ(F2).The final cell constants of a = 10.5660(8) Å, b = 15.5439(12) Å, c = 8.4713(6)
Å, β = 96.3752(17)°, volume = 1382.70(18) Å3, are based upon the refinement of the XYZcentroids of reflections above 20 σ(I).Data were corrected for absorption effects using the MultiScan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.919.
The calculated minimum and maximum transmission coefficients (based on crystal size) are
0.6850 and 0.7454. CCDC deposition number: 1485303.
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The structure was solved and refined using the Bruker SHELXTL Software Package, using the
space group P21/c, with Z = 4 for the formula unit, C16H17NO4.The final anisotropic full-matrix
least-squares refinement on F2 with 192 variables converged at R1 = 4.30%, for the observed data
and wR2 = 10.20% for all data. The goodness-of-fit was 1.045. The largest peak in the final
difference electron density synthesis was 0.184 e-/Å3 and the largest hole was -0.290 e-/Å3 with an
RMS deviation of 0.058 e-/Å3. On the basis of the final model, the calculated density was 1.380
g/cm3 and F (000), 608 e-.

4.5. Cell culture. MCF-7 cells were obtained from the ECACC and were cultured in Minimum
Essential Media with GlutaMAX™-I (Gibco) supplemented with heat-inactivated foetal bovine
serum (10%) (Gibco), penicillin/streptomycin 5000 U/mL (1%) (Gibco) and non-essential amino
acids (1%) (Sigma). Jurkat cells were cultured in RPMI 1640 with GlutaMAX™-I (Gibco)
supplemented

with

heat-inactivated

foetal

bovine

serum

(10%)

(Gibco)

and

penicillin/streptomycin 5000 U/mL (1%) (Gibco). Cells were maintained at 37 °C in 95% air/5%
CO2.
MCF-10a cells were obtained as a kind gift from Dr. Susan McDonnell, UCD School of Chemical
and Bioprocess Engineering and were cultured in Dulbecco's Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F12; Gibco) supplemented with 5% horse serum (Invitrogen), 20 ng/mL
epidermal growth factor (Merck Millipore), 0.5 μg/mL hydrocortisone (Sigma), 100 ng/mL
cholera toxin (Sigma), 10 μg/mL insulin (Sigma), and penicillin/streptomycin 5000 U/mL
(1%)(Gibco).
4.6. Cell viability studies. Cells were seeded in 96-well plates at a density of 2.5 × 104 cells/mL
(200 μL/well). After 24 h, cells were treated with a vehicle control [0.1% (v/v) ethanol] or a range
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of drug concentrations. Plates were incubated for 48 h at 37 °C in 5% CO2. AlamarBlue (20 μL)
(Invitrogen) was added 5 h prior to the endpoint of the assay. Fluorescence was read using the
Spectramax Gemini plate reader with excitation at 544 nm and emission at 590 nm. Blank
fluorescence values were obtained from wells containing only media (200 μL) and alamarBlue (20
μL), and were subtracted from the values obtained for the other wells. The percentage cell viability
was calculated for each drug concentration from FItest/FIcontrol; FItest is the fluorescence intensity of
the drug and FIcontrol is the fluorescence intensity of the control. Experiments were performed in
sextuplicate on three independent occasions for determination of the mean values reported.
4.7. Cell cycle analysis by propidium iodide staining and flow cytometry. Cells were seeded in
T25 flasks at a density of 1 × 105 cells/mL (5 × 105 cells/flask). After 24 hr, cells were treated with
a vehicle control [0.1% (v/v) ethanol] or compound 1 (5, 10 or 20 μM). After treatment for the
appropriate time, cell media was removed and cells were trypsinised. Cell media, trypsinised cells
and PBS washings were combined and centrifuged at 800g for 10 min. The supernatant was
discarded and cells were resuspended in ice-cold PBS (200 μL). Fixing agent [ice-cold 70%
ethanol in PBS (2 mL)] was added slowly while gently vortexing and cell suspensions were stored
at – 20 °C for 24 hr. PBS (2 mL) and FBS (5 μL) were added and cell suspensions were centrifuged
at 800g for 10 min. The supernatant was carefully removed and cells were resuspended in BD
FACSflow (400 μL). Ribonuclease A (1 mg/mL; 25 μL) and propidium iodide (1 mg/mL; 75 μL)
were added and the mixtures were incubated in the dark at 37 °C for 30 min. Samples were
analysed using filter FL-2 on the BD Accuri C6 flow cytometer (BD Biosciences). Data collection
was gated to exclude cellular debris and cell aggregates. At least 10,000 cells per sample were
analysed. Data was analysed using BD CellQuest™. Experiments were performed on three
independent occasions for determination of the mean values reported.
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4.8. Tubulin Polymerization. Tubulin polymerisation was carried out using an assay kit supplied
by Cytoskeleton [Tubulin polymerization HTS assay using >97% pure porcine tubulin, OD-based
(BK004P)], based on the principal that light is scattered by microtubules to an extent that is
proportional to the concentration of the microtubule polymer. Compounds that interact with
tubulin alter its polymerisation, and this can be detected using a spectrophotometer. The
absorbance at 340 nm at 37°C is monitored. The assay was performed as described in version 2.2
of the tubulin polymerisation assay kit manual [31].
4.9. Sedimentation assay and western blotting (tubulin polymerisation). Tubulin
depolymerization was quantified by using a modified version of a previously documented
method.[32] MCF-7 cells were seeded in 6-well plates (1 × 106 cells/well) and then treated with
vehicle [0.1% ethanol (v/v)] or indicated concentrations of compound 1 (1, 10, 20 µM), paclitaxel
(1 µM) or nocodazole (1 µM) for 4 hours. Cells were harvested into MT-preserving buffer (0.1 M
PIPES (pH 6.9), 2 M glycerol, 5 mM MgCl2, 2 mM EGTA, 0.5% Triton X-100, and protease
inhibitors (Roche Diagnostics Ltd, UK) supplemented with 4 μM paclitaxel to maintain stability
of assembled microtubules during isolation. The supernatant containing unpolymerised tubulin
was clarified by centrifugation (20,000g for 45 min) and separated from the pellet containing
polymerized tubulin. The pellet was washed once in MT-preserving buffer before being denatured
in PARP buffer (300 μL)(62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol
blue, 6M urea). Samples were stored at -80 °C. Before use 1M DTT (20 µL) was added to both
the supernatant and pellet samples. 2X Laemmli buffer (180 µL)(62.5 mM Tris-HCl, pH 6.8, 6 M
urea, 2% SDS, 10% glycerol, and 0.01% bromphenol blue) was added to the supernatants. All
samples were boiled at 100 °C for 3 min and loaded equally (30 µg protein). Proteins were
separated on 12% SDS-PAGE gels and transferred onto PVDF membranes (Millipore).
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Membranes were blocked in 5% non-dry fat milk/TBST for 1 h, anti-α-tubulin primary antibody
(1:2500) (Millipore) for 2 h and anti-mouse HRP-conjugated secondary antibody (1:2500)
(Promega) for 1 h at RT. All blots were probed with anti-GAPDH antibody (1:5000) (Millipore)
to confirm equal loading. Proteins were detected using chemiluminescent western blot detection
(Clarity Western ECL substrate) (Bio Rad) on the ChemiDoc MP System (Bio Rad). Experiments
were performed on three independent occasions.
4.10. Evaluation of expression levels of anti-apoptotic proteins Bcl-2 and Mcl-1. MCF-7 cells
were seeded at a density of 5 × 105 cells/flask in T25 flasks. After 48 or 72 hr, whole cell lysates
were prepared from untreated cells or cells treated with vehicle control [ethanol (0.1% v/v)] or
compound 1 (10 μM). Cells were harvested in RIPA buffer supplemented with protease inhibitors
(Roche Diagnostics), phosphatase inhibitor cocktail 2 (Sigma-Aldrich) and phosphatase inhibitor
cocktail 3 (Sigma-Aldrich). Equal quantities of protein (as determined by a BCA assay) were
resolved by SDS-PAGE (12%) followed by transfer to PVDF membranes. Membranes were
blocked in 5% non-dry fat milk/TBST for 1 hr. Membranes were incubated in the relevant primary
antibodies at 4 °C overnight, washed, incubated in horseradish peroxidase conjugated secondary
antibody for 1 hr at rt, and washed again. Enhanced chemiluminescence was used for detection of
protein expression. Western blot analysis was performed using antibodies directed against Mcl-1
(1:1000) (Millipore) or Bcl-2 (1:500) (Millipore) followed by incubation with a horseradish
peroxidase-conjugated anti-mouse antibody (1:1000) (Promega, Madison, WI, USA). All blots
were probed with anti-GAPDH antibody (1:5000) (Millipore) to confirm equal loading. Proteins
were detected using chemiluminescent western blot detection (Clarity Western ECL substrate)
(Bio Rad) on the ChemiDoc MP System (Bio Rad). Experiments were performed on three
independent occasions.
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4.11. Immunofluorescence and confocal microscopy. Confocal microscopy was used to study
the effects of drug treatment on MCF-7 cytoskeleton. For immunofluorescence, MCF-7 cells were
seeded at 1 × 105 cells/mL on eight chamber glass slides (BD Biosciences). Cells were either
untreated or treated with vehicle [1 % ethanol (v/v)], paclitaxel (1 μM), compound 2 (100 nM) or
compound 1 (10 or 20 μM) for 16 h. Following treatment cells were gently washed in PBS, fixed
for 20 min with 4 % paraformaldehyde in PBS and permeabilised in 0.5 % Triton X-100. Following
washes in PBS containing 0.1 % Tween (PBST), cells were blocked in 5 % bovine serum albumin
diluted in PBST. Cells were then incubated with mouse monoclonal anti-α-tubulin−FITC antibody
(clone DM1A) (Sigma) (1:100) for 2 hr at rt. Following washes in PBST, cells were incubated
with Alexa Fluor 488 dye (1:450) for 1 hr at rt. Following washes in PBST, the cells were mounted
in Ultra Cruz Mounting Media (Santa Cruz Biotechnology, Santa Cruz, CA) containing 4,6diamino-2-phenolindol dihydrochloride (DAPI). Images were captured by Leica SP8 confocal
microscopy with Leica application suite X software. All images in each experiment were collected
on the same day using identical parameters. Experiments were performed on three independent
occasions.
4.12. Colchicine-binding site assay. MCF-7 cells were seeded at a density of 1 × 106 cells/well
in 6-well plates and incubated overnight. Cells were treated with vehicle control [ethanol (0.1 %
v/v)], colchicine, compound 2 or compound 1 (all 10 μM) for 2 h. After this time, selected wells
were treated with N,N’-ethylene-bis(iodoacetamide) (EBI) (Santa Cruz Biotechnology) for 1.5 h.
Following treatment, cells were twice washed with ice-cold PBS and lysed by addition of Laemmli
buffer. Samples were separated by SDS-PAGE, transferred to polyvinylidene difluoride
membranes and probed with β-tubulin antibodies (Sigma-Aldrich).
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4.13. Cell viability assay including pre-treatment with N-acetyl cysteine or Trolox. N-Acetyl
cysteine (Sigma) was dissolved in sterile water (100 mM). Trolox (Sigma) was dissolved in ethanol
(1 mM). Fresh solutions were prepared for each experiment. MCF-7 cells were seeded in 96-well
plates at a density of 2.5 × 104 cells/mL. After 23 h, cells were pre-treated with NAC or Trolox (2
μL) for 1 hr. The remainder of the assay was carried out as described for the ‘Cell viability assay’
(above).
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Supplementary material. Effects of compounds 7-13 on the viability of MCF10a human
mammary epithelial cells.
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TABLES
Table 1. Effects of compound 1 and analogues 7-13 on viability of MCF-7 breast cancer cells

Compound

R1

R2

R3

R4

IC50
(μM)

7

H

H

H

H

3.5 ± 0.8

8

OCH3 H

H

H

9.6 ± 2.8

9

H

OCH3 H

H

7.5 ± 1.8

10

H

H

OCH3 H

8.2 ± 0.1

11

OCH3 H

OCH3 H

8.5 ± 1.0

12

H

OCH3 OCH3 H

3.7 ± 0.5

13

OCH3 H

PL

H

OCH3 OCH3

3.4 ± 0.5

OCH3 OCH3 OCH3

1.2 ± 0.6
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FIGURES

Figure 1. Structures of piperlongumine, combretastatin A-4 and analogues.
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Figure 2. Molecular structure of compound 12 with atomic displacement parameters shown
at 50% probability. CCDC deposition number: 1485303.
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Figure 3A. Compound 1 decreases cell viability of Jurkat and MCF-7 cancer cells. Cells were
grown in 96-well plates and treated with compound 1 at 0.1–20 μM for 48 h. Cell viability was
expressed as a percentage of vehicle control [ethanol 1% (v/v)] and was measured by alamarBlue
assay (average of three independent experiments). Figure 3B, C. Effects of compounds 7 and 13
on the viability of MCF10a human mammary epithelial cells. Cells were treated with
compound 7 (B) or 13 (C)(1, 5, 10 and 20 μM) for 48 hr. Cell viability was expressed as a
percentage of vehicle control [ethanol 1% (v/v)] and was measured by alamarBlue assay (average
of three independent experiments). A non-paired two-tailed t-test was used to test for statistical
significance (*, p < 0.05;***, p < 0.001)
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Figure 4. Effect of antioxidant pre-treatment on viability of MCF-7 cells treated with
compound 1 or analogues. MCF-7 cells were seeded at a density of 2.5 x 104 cells/ ml in 96 well
plates and left overnight to adhere. Cells were then pre-treated with NAC (1 mM) or Trolox
(100μM) for 1 hr, followed by either compound 1 (A), compound 7 (B), compound 12 (C) or
compound 13 (D) at the indicated concentrations for 48 hr. Cell viability was expressed as a
percentage of vehicle control [ethanol 1% (v/v)] and was measured by alamarBlue assay (average
of three independent experiments).
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Figure 5. Tubulin-depolymerising chalcones evaluated for effects on ROS
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Figure 6. Effect of antioxidant pre-treatment on viability of MCF-7 cells treated with
tubulin-depolymerising agents. MCF-7 cells were seeded at a density of 2.5 x 104 cells/ ml in 96
well plates and left overnight to adhere. Cells were then pre-treated with NAC (1 mM) or Trolox
(100μM) for 1 hr, followed by either colchicine, compound 2, or compound 14 (10 μM), 15 (10
μM), 16 (10 μM), 17 (10 μM) for 48 hr. Cell viability was expressed as a percentage of vehicle
control [ethanol 1% (v/v)] and was measured by alamarBlue assay (average of three independent
experiments).
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B

Figure 7.A. Effects of compound 1 on the cell cycle and apoptosis in MCF-7 cells. Cells were
treated with either vehicle [V, 0.1% ethanol (v/v)], compound 1 (5, 10 or 20 μM) for 24 or 48 hr.
Cells were then fixed, stained with PI, and analyzed by flow cytometry. Cell cycle analysis was
performed on histograms of gated counts per DNA area (FL2-A). The number of cells with <2N
(sub-G1), 2N (G0G1), and 4N (G2/M) DNA content was determined with CellQuest software.
Values represent the mean ± S.E.M. for three separate experiments. Statistical analysis was
performed using one-way ANOVA followed by Dunnett’s multiple comparison test; (*, p <
0.05;**, p < 0.01; ***, p < 0.001). B. Compound 1 downregulates the expression of antiapoptotic proteins Bcl-2 and Mcl-1. MCF-7 cells were treated with 10 μM of compound 1.
Untreated (UT) and vehicle (EtOH, 0.1 % v/v) controls were also examined. After the required
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time (24 or 48 hr) cells were harvested and separated by SDS PAGE. The membrane was probed
with anti-Bcl-2 or anti-Mcl-1 antibodies and transferred to PVDF membrane. The membrane was
then re-probed for GAPDH as loading control. Results are representative of three separate
experiments.
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A.

B.

Figure 8. Compound 1 induces depolymerization of tubulin in vitro and in MCF-7 cells. A.
Effect of compounds 1 and 7 on in vitro tubulin polymerisation. Purified bovine tubulin and GTP
were mixed in a 96-well plate at 37 oC. Ethanol (1% v/v) was used as a vehicle control. The effect
on tubulin assembly was monitored in a Spectramax 340PC spectrophotometer at 340 nm at 30 s
intervals for 60 min at 37 oC. The results represent the mean for three separate experiments
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performed in duplicate. B. The effect of compound 1 on microtubule dynamics in MCF-7 breast
cancer cells and Jurkat T-lymphocytes was examined by a sedimentation assay and western
blotting. Cells were treated with vehicle [0.1% ethanol (v/v)], 1 (10 μM), paclitaxel or nocodazole
(1μM) for 4 hr before being lysed in MT preserving buffer. Depolymerized and polymerized
fractions were separated by centrifugation and collected as supernatant and pellet fractions
respectively. Samples were separated by western blotting and probed with anti-α-tubulin antibody
[1:1000] and anti-mouse secondary antibody [1:1000]. GAPDH was used as a loading control
[1:1000]. Results are representative of three separate experiments.
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Figure 9. Compound 1 depolymerises the microtubule network of MCF-7 breast cancer cells.
Cells were treated with vehicle control [1% ethanol (v/v)], paclitaxel (1 μM), compound 2 (100
nM) or compound 1 (10 or 20 μM) for 16 h. Cells were fixed in 4% paraformaldehyde and stained
with mouse monoclonal anti-α-tubulin−FITC antibody (clone DM1A) (green), Alexa Fluor 488
dye and counterstained with DAPI (blue). Images were captured by Leica SP8 confocal
microscopy with Leica application suite X software. Representative confocal micrographs of three
separate experiments are shown. Scale bar: 30 μM (top images); 10 μM (bottom images).
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Figure 10. Effects of compound 1 on the inhibition of the bisthioalkylation of Cys239 and
Cys354 of β-tubulin by N,N’-ethylene-bis(iodoacetamide) (EBI) in MCF-7 and HT-29 cells.
MCF-7 and HT-29 cells were treated with vehicle control [ethanol 0.1% (v/v)], 2 (10 μM) or 1 (40
μM) for 2 h; selected samples were then treated with EBI for an additional 1.5 h. Cells were
harvested, lysed and analysed using sedimentation and Western blotting for β-tubulin and βtubulin-EBI adduct. Results are indicative of three separate experiments, performed independently.
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SCHEMES
Scheme 1. Synthesis of compound 1 and analogues 7-13a

a

(i) CH2CHCOCl, NEt3 , DCM, 0 °C to rt, 3 hr, 56%; (ii) Grubbs catalyst (2nd generation), DCM,

reflux, 6 hr, 52%; (iii) NEt3, THF, -20°C, 45 min; (iv) n-BuLi, THF, -78°C, 45 min; anhydride
addition, 1 hr, 61-72%
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